Neurodegenerative Disorder Therapeutics Market Report

Global and Region Neurodegenerative Disorder Therapeutics Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 01, 2022
  • PAGES：167
  • REPORT CODE：GMM968255
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Neurodegenerative Disorder Therapeutics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Neurodegenerative Disorder Therapeuticsmarket, defines the market attractiveness level of Neurodegenerative Disorder Therapeutics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Neurodegenerative Disorder Therapeutics industry, describes the types of Neurodegenerative Disorder Therapeutics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Neurodegenerative Disorder Therapeutics market and the development prospects and opportunities of Neurodegenerative Disorder Therapeutics industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Neurodegenerative Disorder Therapeutics market in Chapter 13.

    By Player:

    • UCB SA

    • Sanofi SA

    • Teva Pharmaceutical Industries Ltd

    • F Hoffmann- La Roche Ltd

    • GlaxoSmithKline PLC

    • H Lundbeck

    • AbbVie Inc

    • Pfizer Inc

    • Novartis AG

    • Bristol Myers Squibb Company

    • Biogen Inc

    • Boehringer Ingeiheim International GmbH

    • Eisai CO LTD

    • Merck KGaA

    • Bayer AG

    By Type:

    • Immunomodulators

    • Interferons

    • Decarboxylase Inhibitors

    • Dopamine Agonists

    • Others

    By End-User:

    • Multiple Sclerosis

    • Parkinson'S Disease

    • Alzheimer'S Disease

    • Spinal Muscular Atrophy

    • Huntington Disease

    • Other Neurodegenerative Disorders

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Neurodegenerative Disorder Therapeutics Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Neurodegenerative Disorder Therapeutics Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Neurodegenerative Disorder Therapeutics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Neurodegenerative Disorder Therapeutics Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Neurodegenerative Disorder Therapeutics Market Analysis and Outlook to 2022

    • 7.1 Global Neurodegenerative Disorder Therapeutics Consumption (2017-2022)

    • 7.2 United States Neurodegenerative Disorder Therapeutics Consumption (2017-2022)

    • 7.3 Europe Neurodegenerative Disorder Therapeutics Consumption (2017-2022)

    • 7.4 China Neurodegenerative Disorder Therapeutics Consumption (2017-2022)

    • 7.5 Japan Neurodegenerative Disorder Therapeutics Consumption (2017-2022)

    • 7.6 India Neurodegenerative Disorder Therapeutics Consumption (2017-2022)

    • 7.7 South Korea Neurodegenerative Disorder Therapeutics Consumption (2017-2022)

    8 Region and Country-wise Neurodegenerative Disorder Therapeutics Market Analysis and Outlook to 2028

    • 8.1 Global Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)

    • 8.2 United States Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)

    • 8.3 Europe Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)

    • 8.4 China Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)

    • 8.5 Japan Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)

    • 8.6 India Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)

    • 8.7 South Korea Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)

    9 Global Neurodegenerative Disorder Therapeutics Market Outlook by Types and Applications to 2022

    • 9.1 Global Neurodegenerative Disorder Therapeutics Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Immunomodulators Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Interferons Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Decarboxylase Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Dopamine Agonists Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Neurodegenerative Disorder Therapeutics Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Multiple Sclerosis Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Parkinson'S Disease Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Alzheimer'S Disease Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Spinal Muscular Atrophy Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Huntington Disease Consumption and Growth Rate (2017-2022)

      • 9.2.6 Global Other Neurodegenerative Disorders Consumption and Growth Rate (2017-2022)

    10 Global Neurodegenerative Disorder Therapeutics Market Outlook by Types and Applications to 2028

    • 10.1 Global Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Immunomodulators Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Interferons Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Decarboxylase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Dopamine Agonists Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Multiple Sclerosis Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Parkinson'S Disease Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Alzheimer'S Disease Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Spinal Muscular Atrophy Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.5 Global Huntington Disease Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.6 Global Other Neurodegenerative Disorders Consumption Forecast and Growth Rate (2022-2028)

    11 Global Neurodegenerative Disorder Therapeutics Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Neurodegenerative Disorder Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Neurodegenerative Disorder Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Neurodegenerative Disorder Therapeutics Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Neurodegenerative Disorder Therapeutics Market Competitive Analysis

    • 14.1 UCB SA

      • 14.1.1 UCB SA Company Details

      • 14.1.2 UCB SA Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 UCB SA Neurodegenerative Disorder Therapeutics Product and Service

    • 14.2 Sanofi SA

      • 14.2.1 Sanofi SA Company Details

      • 14.2.2 Sanofi SA Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Sanofi SA Neurodegenerative Disorder Therapeutics Product and Service

    • 14.3 Teva Pharmaceutical Industries Ltd

      • 14.3.1 Teva Pharmaceutical Industries Ltd Company Details

      • 14.3.2 Teva Pharmaceutical Industries Ltd Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Disorder Therapeutics Product and Service

    • 14.4 F Hoffmann- La Roche Ltd

      • 14.4.1 F Hoffmann- La Roche Ltd Company Details

      • 14.4.2 F Hoffmann- La Roche Ltd Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 F Hoffmann- La Roche Ltd Neurodegenerative Disorder Therapeutics Product and Service

    • 14.5 GlaxoSmithKline PLC

      • 14.5.1 GlaxoSmithKline PLC Company Details

      • 14.5.2 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product and Service

    • 14.6 H Lundbeck

      • 14.6.1 H Lundbeck Company Details

      • 14.6.2 H Lundbeck Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 H Lundbeck Neurodegenerative Disorder Therapeutics Product and Service

    • 14.7 AbbVie Inc

      • 14.7.1 AbbVie Inc Company Details

      • 14.7.2 AbbVie Inc Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 AbbVie Inc Neurodegenerative Disorder Therapeutics Product and Service

    • 14.8 Pfizer Inc

      • 14.8.1 Pfizer Inc Company Details

      • 14.8.2 Pfizer Inc Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Pfizer Inc Neurodegenerative Disorder Therapeutics Product and Service

    • 14.9 Novartis AG

      • 14.9.1 Novartis AG Company Details

      • 14.9.2 Novartis AG Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Novartis AG Neurodegenerative Disorder Therapeutics Product and Service

    • 14.10 Bristol Myers Squibb Company

      • 14.10.1 Bristol Myers Squibb Company Company Details

      • 14.10.2 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product and Service

    • 14.11 Biogen Inc

      • 14.11.1 Biogen Inc Company Details

      • 14.11.2 Biogen Inc Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Biogen Inc Neurodegenerative Disorder Therapeutics Product and Service

    • 14.12 Boehringer Ingeiheim International GmbH

      • 14.12.1 Boehringer Ingeiheim International GmbH Company Details

      • 14.12.2 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product and Service

    • 14.13 Eisai CO LTD

      • 14.13.1 Eisai CO LTD Company Details

      • 14.13.2 Eisai CO LTD Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Eisai CO LTD Neurodegenerative Disorder Therapeutics Product and Service

    • 14.14 Merck KGaA

      • 14.14.1 Merck KGaA Company Details

      • 14.14.2 Merck KGaA Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Merck KGaA Neurodegenerative Disorder Therapeutics Product and Service

    • 14.15 Bayer AG

      • 14.15.1 Bayer AG Company Details

      • 14.15.2 Bayer AG Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Bayer AG Neurodegenerative Disorder Therapeutics Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Neurodegenerative Disorder Therapeutics

    • Figure Neurodegenerative Disorder Therapeutics Picture

    • Table Global Neurodegenerative Disorder Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Neurodegenerative Disorder Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Neurodegenerative Disorder Therapeutics Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Neurodegenerative Disorder Therapeutics Consumption by Country (2017-2022)

    • Figure United States Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Europe Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure China Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Japan Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure India Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Korea Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Global Neurodegenerative Disorder Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure United States Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Immunomodulators Consumption and Growth Rate (2017-2022)

    • Figure Global Interferons Consumption and Growth Rate (2017-2022)

    • Figure Global Decarboxylase Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Dopamine Agonists Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Multiple Sclerosis Consumption and Growth Rate (2017-2022)

    • Figure Global Parkinson'S Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Alzheimer'S Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Spinal Muscular Atrophy Consumption and Growth Rate (2017-2022)

    • Figure Global Huntington Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Other Neurodegenerative Disorders Consumption and Growth Rate (2017-2022)

    • Figure Global Immunomodulators Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Interferons Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Decarboxylase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Dopamine Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Multiple Sclerosis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Parkinson'S Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Alzheimer'S Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Spinal Muscular Atrophy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Huntington Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Neurodegenerative Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Neurodegenerative Disorder Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Neurodegenerative Disorder Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    • Table UCB SA (Foundation Year, Company Profile and etc.)

    • Table UCB SA Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table UCB SA Neurodegenerative Disorder Therapeutics Product and Service

    • Table Sanofi SA (Foundation Year, Company Profile and etc.)

    • Table Sanofi SA Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi SA Neurodegenerative Disorder Therapeutics Product and Service

    • Table Teva Pharmaceutical Industries Ltd (Foundation Year, Company Profile and etc.)

    • Table Teva Pharmaceutical Industries Ltd Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Pharmaceutical Industries Ltd Neurodegenerative Disorder Therapeutics Product and Service

    • Table F Hoffmann- La Roche Ltd (Foundation Year, Company Profile and etc.)

    • Table F Hoffmann- La Roche Ltd Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann- La Roche Ltd Neurodegenerative Disorder Therapeutics Product and Service

    • Table GlaxoSmithKline PLC (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product and Service

    • Table H Lundbeck (Foundation Year, Company Profile and etc.)

    • Table H Lundbeck Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table H Lundbeck Neurodegenerative Disorder Therapeutics Product and Service

    • Table AbbVie Inc (Foundation Year, Company Profile and etc.)

    • Table AbbVie Inc Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table AbbVie Inc Neurodegenerative Disorder Therapeutics Product and Service

    • Table Pfizer Inc (Foundation Year, Company Profile and etc.)

    • Table Pfizer Inc Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Inc Neurodegenerative Disorder Therapeutics Product and Service

    • Table Novartis AG (Foundation Year, Company Profile and etc.)

    • Table Novartis AG Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis AG Neurodegenerative Disorder Therapeutics Product and Service

    • Table Bristol Myers Squibb Company (Foundation Year, Company Profile and etc.)

    • Table Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product and Service

    • Table Biogen Inc (Foundation Year, Company Profile and etc.)

    • Table Biogen Inc Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biogen Inc Neurodegenerative Disorder Therapeutics Product and Service

    • Table Boehringer Ingeiheim International GmbH (Foundation Year, Company Profile and etc.)

    • Table Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product and Service

    • Table Eisai CO LTD (Foundation Year, Company Profile and etc.)

    • Table Eisai CO LTD Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eisai CO LTD Neurodegenerative Disorder Therapeutics Product and Service

    • Table Merck KGaA (Foundation Year, Company Profile and etc.)

    • Table Merck KGaA Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck KGaA Neurodegenerative Disorder Therapeutics Product and Service

    • Table Bayer AG (Foundation Year, Company Profile and etc.)

    • Table Bayer AG Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer AG Neurodegenerative Disorder Therapeutics Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US